Table 1 Recent advances and challenges of bispecific antibodies in solid tumor

EpCAM/CD3

Catumaxomab

Completed

II

NCT01065246

Malignant Ascites Due to Epithelial Carcinoma

Completed

II

NCT00377429

Ovarian Cancer

Completed

II

NCT00464893

Gastric Cancer, Gastric Adenocarcinoma

Completed

II

NCT01246440

Ovarian Cancer

Completed

II

NCT01504256

Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Completed

II

NCT00326885

Malignant Ascites

Completed

II

NCT01815528

Recurrent Epithelial Ovarian Cancer

Completed

III

NCT00822809

Cancer, Neoplasms

Completed

II

NCT00563836

Ovarian Cancer, Epithelial Ovarian Cancer

Completed

II/III

NCT00836654

EpCAM Positive Cancer

Completed

II

NCT00352833

Gastric Cancer, Gastric Adenocarcinoma

Completed

II

NCT00189345

Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Not recruiting

I/II

NCT04799847

Bladder Cancer

Recruiting

I

NCT04819399

Urinary Bladder Neoplasms

Recruiting

III

NCT04222114

Stomach Neoplasms

Terminated

I

NCT01320020

Epithelial Cancer

Terminated

II

NCT01784900

Gastric Peritoneal Carcinomatosis

MT110 (AMG110)

Completed

I

NCT00635596

Solid Tumors

CEA/CD3

MT111/AMG211/MEDI-565

Completed

I

NCT01284231

Gastrointestinal Adenocarcinomas

Terminated

I

NCT02291614

Gastrointestinal Cancer

RO6958688 (RG7802)

Completed

I

NCT02650713

Solid Tumors

Completed

I

NCT02324257

Solid Tumors

Recruiting

III

NCT03337698

NSCLC

CEA/HSG

TF2 (IMP288)

Completed

III

NCT01221675

SCLC, CEA-expressing NSCLC

Withdrawn

I

NCT01273402

Metastatic Colorectal Cancer

Completed

II

NCT02587247

Metastatic Colorectal Cancer

Completed

I

NCT00860860

Colorectal Neoplasms

Unknown

III

NCT02300922

Metastatic Colorectal Cancer

PSMA/CD3

Pasotuxizumab (BAY 2010112, MT112, AMG 212)

Completed

I

NCT01723475

Prostatic Neoplasms

Acapatamab (AMG160)

Recruiting

I

NCT04822298

Non-Small Cell Lung Cancer

Recruiting

I

NCT03792841

Metastatic Castration-resistant Prostate Cancer

Recruiting

III

NCT04631601

Metastatic Castration-resistant Prostate Cancer

HPN424

Recruiting

III

NCT03577028

Advanced Prostate Cancer

MOR209/ES414

Completed

I

NCT02262910

Metastatic Castration-resistant Prostate Cancer

CC-1

Recruiting

I

NCT04104607

Metastatic Castration-resistant Prostate Cancer

Not yet recruiting

III

NCT04496674

Lung Cancer Squamous Cell

EGFR/MET

Amivantamab (JNJ-61186372)

Approved for marketing

NCT04599712

Metastatic NSCLC

Recruiting

II

NCT04945733

Stomach Neoplasms, Esophageal Neoplasm

Recruiting

II

NCT04965090

Metastatic NSCLC

Recruiting

III

NCT04538664

Metastatic NSCLC

Not recruiting

III

NCT04988295

NSCLC

Recruiting

I

NCT04606381

Advanced Solid Malignancies

Recruiting

III

NCT04487080

NSCLC

Recruiting

I

NCT02609776

NSCLC

Recruiting

I

NCT04077463

NSCLC

HER2/CD3

Ertumaxomab

Terminated

III

NCT01569412

HER2/Neu Positive Advanced Solid Tumors

Terminated

II

NCT00351858

Metastatic Breast Cancer

Terminated

II

NCT00522457

Metastatic Breast Cancer

Terminated

II

NCT00452140

Metastatic Breast Cancer

HER2/HER3

MM111

Completed

I

NCT01097460

Breast Neoplasms

Completed

I

NCT00911898

HER2 Amplified Solid Tumors

Completed

I

NCT01304784

HER2 Amplified Solid Tumors

Terminated

II

NCT01774851

HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal Junction and Stomach

HER2/HER3

Zenocutuzumab (MCLA-128)

Recruiting

III

NCT02912949

Solid Tumors Harboring NRG1 Fusion

GPC3/CD3

ERY974

Completed

I

NCT02748837

Solid Tumors

Recruiting

I

NCT05022927

Hepatocellular Carcinoma

PD1/PDL1

LY3434172

Completed

I

NCT03936959

Advanced Cancer

PDL1/TIM3

LY3415244

Terminated

I

NCT03752177

Advanced Cancer

PD-1/CTLA4

MEDI5752

Active

I

NCT03819465

Metastatic NSCLC

Recruiting

I

NCT03530397

Advanced Renal Cell Carcinoma

Recruiting

I

NCT04522323

Advanced Solid Tumors

DLL4/VEGF

Navicixizumab (OMP-305B83)

Not recruiting

III

NCT05043402

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Completed

I

NCT02298387

Advanced Solid Tumor Malignancies

Completed

I

NCT03030287

Ovarian, Peritoneal or Fallopian Tube Cancer

Terminated

I

NCT03035253

Metastatic Colorectal Cancer

DLL4/VEGF

ABL001 (NOV1501)

Recruiting

III

NCT04492033

Advanced Solid Tumors

Completed

I

NCT03292783

Advanced Solid Tumors

CD3/GPA33

MGD007

Completed

I

NCT02248805

Colorectal Carcinoma

Active

III

NCT03531632

Metastatic Colorectal Cancer

CD64/EGFR

MDX447

Completed

I

NCT00005813

Brain and Central Nervous System Tumors